Rubius Therapeutics, which is developing red-cell therapeutics (RCTs) as a new class of medicines to address a range of indications, has raised $120m in a highly oversubscribed private financing.
eFFECTOR Therapeutics has entered into a clinical collaboration and supply agreement with Pfizer and Merck to evaluate the combination of two immuno-oncology agents in patients with microsatellite stable colorectal cancer (CRC).
BiondVax Pharmaceuticals, which is developing a universal vaccine for all strains of influenza, has signed an agreement with the European Investment Bank (EIB) for a €20m loan.
Basilea Pharmaceutica International has signed a license agreement with Pfizer for its marketed antifungal Cresemba (isavuconazole) to treat life-threatening invasive mold infections.
Accenture and 1QBit have partnered with Biogen to develop a quantum-enabled molecular comparison application that could considerably improve advanced molecular design to accelerate drug discovery for complex neurological conditions like multiple sclerosis, Alzheimer’s, Lou Gehrig’s Disease and Parkinson’s.
A consortium featuring entities affiliated with GL Capital Management GP, Bank of China Group Investment (BOCGI), CDH Investments, Ascendent Capital Partners and Boying will acquire all the outstanding shares of SciClone Pharmaceuticals for $11.18 per share in cash.
Eleven Biotherapeutics signed a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) to assess its late-clinical-stage fusion protein Vicinium (VB4-845) combined with AstraZeneca’s immune checkpoint inhibitor Imfinzi (durvalumab) to treat nonmuscle invasive bladder cancer (NMIBC).
Sevion Therapeutics has agreed to acquire Eloxx Pharmaceuticals, which is focused on developing therapeutics for genetic diseases caused by non-sense mutations.
Scientists at Florida’s The Scripps Research Institute (TSRI) have succeeded in modeling a key part of a virus that sickens several people in West Africa.
Taiwan-based OBI Pharma has agreed to acquire Threshold Pharmaceuticals' TH-3424, a novel small-molecule prodrug that selectively targets cancers overexpressing the enzyme aldo-keto reductase 1c3 (AKR1C3).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.